(SeaPRwire) – By: Ethan Gallagher
Two RSV vaccines entered the American market in 2023. GlaxoSmithKline and Pfizer each brought products that carried enormous expectations. Clinical trials had shown impressive efficacy numbers. The concern on Wall Street and in boardrooms was simple and immediate. Real-world results might fall short of those headline figures. Senior citizens in the U.S. face thousands of deaths from RSV every year. Anything less than stellar performance would trigger a different kind of reckoning.
The data did not disappoint. A study published September 18 in JAMA Network Open tracked 14.8 million Medicare-enrolled seniors aged 65 and older. The FDA-sponsored research found the vaccines reduced RSV-related hospitalization or death by approximately 80 percent. Both products performed at similar levels. This finding echoed trial results closely enough to silence the skeptics who worried the post-COVID-era vaccine rollout might not translate to actual public health protection.
Dr. Edward Walsh, professor of medicine at the University of Rochester, described the real-world outcomes as deeply reassuring. He noted that previous smaller studies had mirrored trial data with surprising consistency. This new analysis covered a population vastly larger than anything seen before. Some researchers had raised legitimate concerns during the trial phase. RSV circulation was unusually low while the pandemic dominated medical attention. That environment made it harder to measure true vaccine impact under normal endemic conditions.
The study did reveal one notable pattern. Vaccinated seniors were more likely to live in affluent areas and more likely to have received flu and COVID shots as well. That correlation raised a straightforward question. Were survival numbers inflated by better healthcare access rather than vaccine potency alone. The researchers ran controls to test that variable. The answer came back clean. The high efficacy remained intact even when access to care was factored out.
The next puzzle involves booster strategy. A second RSV vaccine launched in 2024, this one from Moderna using mRNA technology. Uptake dropped noticeably among the target population. Many people in that demographic already received the original shot during its first year of availability. The scientific question now is whether another dose two or three years later refreshes waning immunity.
Walsh pointed to a critical uncertainty here. The second vaccination does not produce the same vigorous antibody response as the initial dose. Whether that matters for long-term protection remains unknown. Flu vaccines require annual shots primarily because the virus strains shift each season. RSV behaves differently. There is no comparable strain turnover driving the same booster cadence.
Researchers have one more interesting direction they may pursue. The goal of a respiratory vaccine covering multiple viruses simultaneously is already on the table. The theory involves stimulating the innate immune system in a broad, non-specific way that blocks any viral infection rather than targeting a single pathogen. Walsh referenced research showing that recovering from one virus sometimes protects against catching another. Immunologists are exploring whether that natural phenomenon can be replicated through vaccination strategy.
The implications for the vaccine market are substantial. A pan-respiratory product would reshape dosing schedules, reduce the frequency of boosters, and potentially command premium pricing in a consolidated field. Pfizer and GSK will need to decide whether to invest heavily in next-generation formulations or lean into the booster revenue model that the current data supports. Moderna’s earlier entry suggests at least one competitor is betting on the mRNA platform’s flexibility to accelerate that timeline.
Author bio: Ethan Gallagher, a Silicon Valley Hardware Architect and Infrastructure Strategist with over 20 years covering the intersection of biotech innovation and market disruption.